Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Inhibrx Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
No intraday reading yet this session.
Inhibrx Biosciences, Inc. has 1 disclosed supplier and 4 disclosed customers. Each one is named in an SEC filing, either Inhibrx Biosciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In January 2025, we borrowed a total of $100.0 million from Oxford under a loan and security agreement, or the 2025 Loan Agreement.”
FILING10-K0002007919-26-000006cik 0002007919
“License fee revenue during the year ended December 31, 2024 was $0.2 million and consisted of revenue related to our license agreement with Regeneron Pharmaceuticals, Inc., which we recognized following the grant of two six-month extensions of the option term during the year, each for revenue of $0.1 million.”
FILING10-K0002007919-26-000006cik 0002007919
“In May 2024, we completed a successful Merger and Separation with Sanofi for the 4 purchase of our INBRX-101 program for alpha-1 antitrypsin deficiency disorder.”
FILING10-K0002007919-26-000006cik 0002007919
“License fee revenue during the year ended December 31, 2025 was $1.3 million and consisted of revenue related to Scithera License Agreement which we recognized following the completion of the transfer of all licenses, related materials, and know-how.”
FILING10-K0002007919-26-000006cik 0002007919
“Pursuant to the Merger (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer; and (ii) by way of the Separation, we acquired the assets and liabilities and corporate infrastructure associated with its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, as well as the remaining close-out obligations related to its previously terminated program, INBRX-105.”
FILING10-K0002007919-26-000006cik 0002007919
Watchlist prices, news filtered to it, and its next report on your desk.
INBX (Inhibrx Biosciences, Inc.) has 1 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: SNY −2.03%, in industrials & materials.